| Not Yet Recruiting | Gut Microbiome in DLBCL Treated With Glofitamab NCT07498920 | Peking Union Medical College Hospital | — |
| Not Yet Recruiting | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human NCT07259070 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma NCT07162012 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Recruiting | Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patient NCT07070648 | Fudan University | — |
| Recruiting | Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy NCT06758037 | First Affiliated Hospital of Ningbo University | Phase 2 |
| Recruiting | A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLB NCT06779435 | Ruijin Hospital | — |
| Not Yet Recruiting | CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) NCT06750991 | Ruijin Hospital | Phase 2 |
| Recruiting | CR-CHOP+X in Previously Untreated DEL NCT06701357 | Ruijin Hospital | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Not Yet Recruiting | Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL NCT06652165 | Ruijin Hospital | Phase 2 |
| Recruiting | A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma NCT07335120 | The Clatterbridge Cancer Centre NHS Foundation Trust | — |
| Recruiting | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients NCT06569485 | Sun Yat-sen University | Phase 2 |
| Recruiting | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplat NCT06521255 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 |
| Recruiting | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies NCT06014762 | Poseida Therapeutics, Inc. | Phase 1 |
| Recruiting | Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019 | Schrödinger, Inc. | Phase 1 |
| Recruiting | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies NCT05653271 | Acepodia Biotech, Inc. | Phase 1 |
| Unknown | A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma NCT05852028 | Ruijin Hospital | — |
| Active Not Recruiting | Study of Oral MRT-2359 in Selected Cancer Patients NCT05546268 | Monte Rosa Therapeutics, Inc | Phase 1 / Phase 2 |
| Unknown | SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 an NCT05498636 | The Affiliated Hospital of Qingdao University | Phase 1 / Phase 2 |
| Active Not Recruiting | Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) NCT05253118 | Seoul National University Hospital | Phase 2 |
| Recruiting | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) NCT05487170 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma NCT05381506 | Sun Yat-sen University | Phase 2 |
| Completed | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL NCT05233033 | Kymera Therapeutics, Inc. | Phase 1 |
| Unknown | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL NCT05093140 | Sun Yat-sen University | Phase 2 |
| Unknown | Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy NCT05414162 | University Hospital, Bonn | — |
| Withdrawn | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL NCT05176691 | Hutchmed | Phase 1 |
| Recruiting | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed o NCT05139017 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Active Not Recruiting | Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patie NCT04974216 | The Lymphoma Academic Research Organisation | Phase 2 |
| Unknown | Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBC NCT04994626 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Ref NCT05039658 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Active Not Recruiting | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL NCT04594798 | University of Rochester | Phase 2 |
| Recruiting | Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refrac NCT05552937 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 |
| Suspended | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL NCT04855253 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Terminated | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocy NCT04806035 | TG Therapeutics, Inc. | Phase 1 |
| Unknown | R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study NCT04842487 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Split-Dose R-CHOP for Older Adults With DLBCL NCT03943901 | University of Wisconsin, Madison | Phase 2 |
| Recruiting | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With R NCT04512716 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Withdrawn | Diet, Physical Activity and Body Composition Changes During R-CHOP NCT04293900 | George Washington University | — |
| Active Not Recruiting | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies NCT04072458 | Bio-Path Holdings, Inc. | Phase 1 |
| Completed | 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) NCT04566978 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Recruiting | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab NCT04332822 | Nordic Lymphoma Group | Phase 3 |
| Recruiting | Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 / Phase 2 |
| Completed | Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma NCT07041827 | The Netherlands Cancer Institute | — |
| Completed | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors NCT03997968 | Cyteir Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Ne NCT03954106 | Jazz Pharmaceuticals | Phase 2 |
| Terminated | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma NCT04082936 | IGM Biosciences, Inc. | Phase 1 / Phase 2 |
| Completed | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies NCT04088890 | Matthew Frank | Phase 1 |
| Recruiting | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma NCT04002947 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance NCT03731234 | Fondazione Italiana Linfomi - ETS | Phase 2 |
| Recruiting | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Larg NCT03758989 | University of Rochester | Phase 2 |
| Active Not Recruiting | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL NCT03463057 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Enrolling By Invitation | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells NCT03628612 | Autolus Limited | Phase 2 |
| Completed | Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL NCT06150053 | University Hospital, Saarland | — |
| Active Not Recruiting | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma NCT03625037 | Genmab | Phase 1 / Phase 2 |
| Completed | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) NCT03527147 | Acerta Pharma BV | Phase 1 |
| Recruiting | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy NCT03356054 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 1 / Phase 2 |
| Completed | SMOLY : Phenotype and Functions of Monocyte Subtypes in High Grade B Lymphoma: Towards New Biomarkers? NCT03672682 | Rennes University Hospital | — |
| Terminated | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy NCT03225924 | The Lymphoma Academic Research Organisation | Phase 1 / Phase 2 |
| Unknown | High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in D NCT03123718 | Chonnam National University Hospital | Phase 3 |
| Terminated | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies NCT03205046 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Terminated | Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle NCT02488512 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Active Not Recruiting | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chem NCT02889523 | The Lymphoma Academic Research Organisation | Phase 1 / Phase 2 |
| Terminated | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK- NCT02698189 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma NCT02702141 | Seagen Inc. | Phase 1 |
| Completed | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers NCT01563302 | Ionis Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans NCT01287923 | Rennes University Hospital | — |
| Completed | Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ P NCT01285765 | The Lymphoma Academic Research Organisation | Phase 3 |
| Completed | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects NCT01205737 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 |
| Approved For Marketing | Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL NCT04300803 | MorphoSys AG | — |